Plasminogen Activator Inhibitor (PAI-1), Antigen

Overview

  • EPIC Code:
  • LAB2639
  • Soft Test Code:
  • Send Out Test Code:
  • 36555
Alternate Names
  • PAI-1
  • PAI1
  • Plasminogen Activator Inhibitor Antigen
Clinical Significance

Increased activity is associated with increased risk of arterial thrombosis, such as with unexplained premature myocardial infarction. As an acute phase reactant, the activity is increased after an acute event. Studies suggest PAI-1 may be a prognostic marker in early stage breast cancer.


Specimen Collection & Preparation

Specimen Requirements:

-OR-

1.0 mL Plasma from a Blue Top Tube - 3.2% Na Citrate in a Plastic Vial
Minimum Volume:
0.3 mL Plasma*

* This volume does not allow for repeat testing

Processing Instructions:

Centrifuge and separate plasma from cells

Pipette into plastic vial

ReCentrifuge just the plasma and pipette again into another plastic vial

Freeze Immediately (< or = -40° C if possible)


Rejection Criteria:

Ambient specimen

Refrigerated specimen

Gross hemolysis

Gross lipemia


Transport and Storage:
  • Ambient (18-24°C): Unacceptable
  • Refrigerated (2-8°C): Unacceptable
  • Frozen (-20° C or colder): 30 Days

    Transport 

  • Ultra Frozen (-70° C or colder or by dry ice): 1 Year

Clinical Interpretation

Reference Range:

Refer to Interpretive Results


Methodology:
  • Enzyme Linked Immunosorbent Immunoassay (ELISA)
Clinical Significance

Increased activity is associated with increased risk of arterial thrombosis, such as with unexplained premature myocardial infarction. As an acute phase reactant, the activity is increased after an acute event. Studies suggest PAI-1 may be a prognostic marker in early stage breast cancer.


Production Schedule

Sites Performed
  • Quest - Chantilly to San Juan Capistrano
Days Performed
Thursday
Departments
  • Sendouts - Clinical
Turn Around Time

8 to 13 days


Coding & Compliance

CDM

00910607


CPT Coding

85415